Changes in Hong Kong stocks | China Biopharmaceuticals (01177) rose more than 6% TRD205 “AT2R antagonist” has been included in the CDE list of breakthrough therapeutics

The Zhitong Finance App learned that China Biopharmaceuticals (01177) rose more than 6%. As of press release, it had risen 6.07% to HK$5.41, with a turnover of HK$452 million.

According to the news, China Biopharmaceutical announced that the new national class 1 drug TRD205 “AT2R antagonist” independently developed by Beijing Tide Pharmaceutical Co., Ltd. (“Beijing Tide”), a subsidiary of the group, has completed phase II clinical trials for chronic post-operative neuropathic pain (CPSNP). Based on the positive results of this trial, TRD205 has been added to the list of breakthrough therapeutics by the Drug Evaluation Center (CDE) of the China National Drug Administration.

TRD205 has now been included as a breakthrough treatment. It is mainly based on a multi-center, randomized, double-blind, placebo-parallel controlled, and dose-exploration phase II clinical trial to evaluate its efficacy and safety in treating chronic post-operative neuralgia. As one of the representative results of the transformation of the Group's second-generation AI drug discovery platform, TRD205 further verified the practical application value of AI technology in molecular structure generation and candidate screening. The Group will continue to promote follow-up clinical development of TRD205 and expand its exploration in other chronic pain indications such as diabetic peripheral neuropathic pain (DPNP) to provide new solutions for the treatment of chronic nerve pain.